ClinicalTrials.gg
RecruitingNCT03062085Updated May 11, 2026

Shanghai High Myopia Study

An observational study in High Myopia, Cataract and Visual Outcome, sponsored by Shanghai High Myopia Study Group. Recruiting at 1 site in China. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Shanghai High Myopia Study Group · Observational

How we know

From the registry’s dates

  • Started Jan 2015; still recruiting 11 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60,000
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Cataract with a site in China — 39 open to participants now, 49 under way, none of them phase 3. Cataract · China.

Planned enrollment
2nd of 73
60,000 · median 120
Started
2015
with 6 others
Observational
73 of 184
19 open now
Primary completion
2035-12
later than 48 of 48 live
Registered
47th of 184
by date

Among the 184 studies in Cataract with a site in China, this one is the 2nd largest by planned enrollment of the 73 observational ones that give a count, is one of 7 that started in 2015, is one of 73 observational ones, reaches primary completion later than 48 of the 48 other live ones, and was the 47th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

39 of the 184 studies in Cataract with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Cataract with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term visual outcome of the cataract surgery using a large-scale and comprehensive database of high myopic cataract and age-related cataract patients. The investigators will further investigate into the various genetic and environmental factors that may contribute to the pathogenesis of high myopic cataract.

Read the detailed description

High myopic cataract (HMC) has become a major high-risky type of cataract in China, which accounts for nearly 30% of cataract in recent years. Compared to age-related cataract, HMC is characterized with earlier onset, severer lens opacities, higher incidence of vitreoretinopathy and postoperative complications compared to age-related cataract(ARC).

The main purpose of this study is to evaluate the long-term visual outcome of the cataract surgery using a large-scale and comprehensive database of high myopic cataract, when compared to those age-matched ARC patients.

On the other hand, due to the lack of research in the pathogenesis of HMC, it is difficult for the investigators to precisely evaluate its risk and prognosis, and to improve its prevention and treatment. The previous study of investigators majored in a large-sample analysis on the clinical features and related genes of HMC. After preliminary screening, eight genes were selected for further investigation: 1) genes related to pathogenesis of HMC: CRYAA/ GSTP1/ TXNRD2;2) genes related to vitreoretinopathy: MCP1/ VEGFA/ CFH; 3) genes related to postoperative complications: TGFB2/ CERS2. In the present study, in order to establish a risk model of HMC from the aspect of precision medicine, the investigators are preparing to set up a comprehensive clinical database for further sequencing of selected genes (including exons, promoters, 5' UTR and 3' UTR sequences) on a large scale, to intensively investigate into the sites and functions of single nucleotide polymorphism (SNP) correlated with clinical features of HMC.

The research aim to evaluate the long-term visual outcome of the cataract surgery using a large-scale and comprehensive database of high myopic cataract, to thoroughly illustrate the influence of HMC-related genes to its prognosis and to elucidate the pathogenesis of HMC, for further promotion in the disease prevention and prognosis as well.

03

Conditions studied

  • High Myopia
  • Cataract
  • Visual Outcome
  • Genetic Anticipation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cataract patients who will undergo cataract surgery in Eye and ENT Hospital of Fudan University.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of cataract
  • Must be able to cooperate with the ophthalmic examination

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of mental illness
  • Mentally disabled
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • High myopic cataract group

    Cataract patients with high myopia.

    Other: Cataract

  • Age-related cataract group

    Age-related cataract patients.

    Other: Cataract

  • Ametropic cataract group

    Cataract patients with ametropia.

    Other: Cataract

Interventions

  • OtherCataract

    The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.

06

What researchers measure

Primary outcomes

  1. Differences in the clinical phenotypes and visual outcomes of high myopic cataract patients

    Cataract type and severity of high myopic cataract patients are evaluated using LOCSIII grading system. Visual outcomes are also evaluated including visual acuity with or without correction, intraocular pressure, fundus function, contrast sensitivity and other visual outcome measurements.

    Time frame: Follow-up until five years after surgery

  2. Differences in the clinical phenotypes and visual outcomes of age-related cataract patients

    Cataract type and severity of age-related cataract patients are evaluated using LOCSIII grading system. Visual outcomes are also evaluated including visual acuity with or without correction, intraocular pressure, fundus function, contrast sensitivity and other visual outcome measurements.

    Time frame: Follow-up until five years after surgery

  3. Differences in the clinical phenotypes and visual outcomes of ametropic cataract patients

    Cataract type and severity of ametropic cataract patients are evaluated using LOCSIII grading system. Visual outcomes are also evaluated including visual acuity with or without correction, intraocular pressure, fundus function, contrast sensitivity and other visual outcome measurements.

    Time frame: Follow-up until five years after surgery

Secondary outcomes

  1. Genetic diversity based on biological specimen samples of three groups

    Sequencing of selected genes (including exons, promoters, 5' UTR and 3' UTR sequences) on a large scale to intensively investigate into the sites and functions of single nucleotide polymorphism (SNP) correlated with clinical features of HMC, compared to age-related cataract and ametropic cataract patients.

    Time frame: Analyzed within six months after surgery

Other outcomes

  1. Difference in the surgical procedure of three groups

    To compare the difference in the surgical procedure of three groups.

    Time frame: Recorded on the surgery day for further analysis

  2. Difference in the Diagnostic test of three groups

    To compare the difference in the diagnostic test of three groups.

    Time frame: Recorded before the surgery day for further analysis

  3. Difference in the complications of the cataract surgery of three groups

    To compare the prevalence of complications of the cataract surgery in HMC,ARC and ametropic cataract patients.

    Time frame: Follow-up until five years after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhang Y, Zhang S, Zhang K, Lu Y, Zhu X. Characteristics of the Corneal Endothelium in Elderly Adults with High Myopia. Phenomics. 2025 Jan 27;4(6):562-569. doi: 10.1007/s43657-024-00186-6. eCollection 2024 Dec. PubMed 40061825 ↗
  • Hu X, Qi J, Cheng K, He W, Zhang K, Zhao C, Lu Y, Zhu X. Effectiveness of prophylactic capsular tension ring implantation during cataract surgery in highly myopic eyes. J Cataract Refract Surg. 2024 Oct 1;50(10):1030-1036. doi: 10.1097/j.jcrs.0000000000001495. PubMed 39313860 ↗
  • He W, Wei L, Liu S, Huang Z, Qi J, Zhang K, Meng J, Du Y, Lu Y, Zhu X. Role of Optic Nerve Head Characteristics in Predicting Intraocular Pressure Spikes after Cataract Surgery in Highly Myopic Eyes. Ophthalmol Ther. 2023 Aug;12(4):2023-2033. doi: 10.1007/s40123-023-00714-z. Epub 2023 May 13. PubMed 37178442 ↗
  • He W, Cheng K, Zhao L, Liu S, Huang Z, Zhang K, Du Y, Zhou X, Lu Y, Zhu X. Long-Term Outcomes of Posterior Capsular Opacification in Highly Myopic Eyes and Its Influencing Factors. Ophthalmol Ther. 2023 Aug;12(4):1881-1891. doi: 10.1007/s40123-023-00711-2. Epub 2023 May 3. PubMed 37138195 ↗
  • Meng J, Chen Y, Cheng K, Qi J, Du Y, Yao Y, He W, Zhang K, Lu Y, Zhu X. LONG-TERM PROGRESSION PATTERN OF MYOPIC TRACTIONAL MACULOPATHY: Outcomes and Risk Factors. Retina. 2023 Jul 1;43(7):1189-1197. doi: 10.1097/IAE.0000000000003791. PubMed 36977327 ↗
  • Lu Q, He W, Qian D, Lu Y, Zhu X. Measurement of crystalline lens tilt in high myopic eyes before cataract surgery using swept-source optical coherence tomography. Eye Vis (Lond). 2020 Mar 6;7:14. doi: 10.1186/s40662-020-00176-5. eCollection 2020. PubMed 32161773 ↗

Individual participant data

Plan to share: Undecided — Undecided.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2015 (actual). Primary completion is estimated for Dec 2035, 251 months after the start.

Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's planned 251 months is above that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Feb 23, 2017
StartActual
Jan 1, 2015
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2045
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03062085
Lead sponsor
Shanghai High Myopia Study Group
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Jan 1, 2015
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2045 (estimated)
Last update
May 11, 2026

Study contacts

Yi Lu, M.D.
Contact
luyieent@163.com
(86)021-64377134
Yi Lu, M.D.
study chair · Eye and ENT Hospital of Fudan University
Xiangjia Zhu, M.D.
study director · Eye and ENT Hospital of Fudan University
Keke Zhang, M.D.
principal investigator · Eye and ENT Hospital of Fudan University
Wenwen He, M.D.
principal investigator · Eye and ENT Hospital of Fudan University
Yu Du, B.S.
principal investigator · Eye and ENT Hospital of Fudan University
Yinglei Zhang, M.D.
principal investigator · Eye and ENT Hospital of Fudan University
Zhennan Zhao, Ph.D.
principal investigator · Eye and ENT Hospital of Fudan University
Ruiqi Chang, B.S.
principal investigator · Eye and ENT Hospital of Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion